MarginsXMarginsX
Home › Markets › Health Care › CUE

Cue Biopharma Inc. (CUE)

CUE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$14.10
-12.53% on the day
Market cap
$102.4M
Micro cap
Revenue · 2025
$27.5M
+195.7% on 2024
Net income · 2025
-$26.6M
-96.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/0001193125-26-108287-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCUE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001645460
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$27.5M
Net income-$26.6M
Operating income-$26.6M
Net margin-96.9%
Operating margin-96.7%
Revenue growth+195.7%
Cash$27.1M
Total assets$42.2M
P/E (computed)Net income was not positive
P/S (computed)3.7×

Warning signs

Cash runway
4.2 months
$17.4M cash at June 30, 2026
Share count, 1 year
+183.6%
2025-08-08 to 2026-08-12 · +384.7% over 3 years
Going-concern doubt
No
10-Q filed August 14, 2026
Insider net buying, 12 months
-$1.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-14
Cash and burn$17.4M cash; operating cash flow -$12.5M a quarter.Report 2026-06-30
Shares outstanding7,264,414 (2026-08-12); 76,845,904 a year earlier; 44,959,548 three years earlier. 1y figure adjusted for split (1-for-30 overall); 3y figure adjusted for split (1-for-30 overall).Cover page 2026-08-12
Reverse splits, 3 years1; latest 1-for-30 on 2026-04-24Source 2026-04-24
Shelf and offerings, 12 months4 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-12-19
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorRSM US LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $100K, sold $2.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$7.9M-$153.1M-$29.0M$17.4MNo debt tags$37.7M10-Q 2026-08-14
Q1 2026
2026-03-31
$5.7M-$5.2M-$10.9M$16.4MNo debt tags$32.7M10-Q 2026-05-14
Q4 2025
2025-12-31
$21.9M$1.6M-$1.1M$27.1MNo debt tags$27.5M10-K 2026-03-16
Q3 2025
2025-09-30
$2.1M-$7.4M-$9.0M$11.7MNo debt tags$7.1M10-Q 2025-11-12
Q2 2025
2025-06-30
$3.0M-$8.5M-$3.4M$27.5MNo debt tags$8.3M10-Q 2026-08-14
Q1 2025
2025-03-31
$421K-$12.3M-$8.2M$13.1M$100K$8.0M10-Q 2026-05-14
Q4 2024
2024-12-31
$1.6M-$9.5M-$9.0M$22.5M$37K$9.3M10-K 2026-03-16
Q3 2024
2024-09-30
$3.3M-$8.7M-$7.5M$32.4M$1.0M$9.5M10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-08-12
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-08-14
Latest current report8-K2026-11-16
Latest proxyDEF 14A2026-05-21

Source: SEC EDGAR submissions feed, 557 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.9%
1 month-17.6%
3 months-48.1%
Year to date+76.2%
1 year-13.3%
From 52-week high-57.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OGIOrganigram Global Inc. Common Shares$0.7240-12.62%$102.2M
UNCYUnicycive Therapeutics Inc.$3.70+4.23%$103.1M
ORGOOrganogenesis Holdings Inc.$0.8031-0.86%$104.2M
DERMJourney Medical Corporation$3.70-14.55%$104.5M
CLLSCellectis S.A.$1.04-11.86%$104.5M
ADAGAdagene Inc.$1.60-6.43%$105.7M
BGMBGM Group Ltd.$8.01+1.71%$107.0M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier